Mycophenolate mofetil in dermatology

Journal of the American Academy of Dermatology

Volumn 60, Issue 2, 2009, Pages 183-199

  Orvis, Alissa K ^a   Wesson, Stanton K ^a   Breza Jr , Thomas S ^a   Church, Ann A ^a   Mitchell, Christina L ^a   Watkins, Shannon W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTACID AGENT; AZATHIOPRINE; COLESTYRAMINE; CYCLOSPORIN; DAPSONE; FUROSEMIDE; GANCICLOVIR; GLUCOCORTICOID; IRON; LEVONORGESTREL; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PENCICLOVIR; POLYCARBOPHIL CALCIUM; POLYSORBATE 80; PREDNISONE; PROBENECID; PSORALEN; QUINOLONE DERIVATIVE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; SEVELAMER; STEROID; VALACICLOVIR;

ABDOMINAL PAIN; ABNORMAL FECES; ABSCESS; ABSENCE OF SIDE EFFECTS; ACNE; ACUTE GRAFT VERSUS HOST DISEASE; ADD ON THERAPY; ADJUVANT THERAPY; AMINOTRANSFERASE BLOOD LEVEL; ANAL COMPLAINT; ANEMIA; ASPERGILLOSIS; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BACKACHE; BEHCET DISEASE; BLASTOMYCOSIS; BLISTER; BREAST CANCER; BRONCHITIS; BULLOUS PEMPHIGOID; BURNING SENSATION; CANDIDIASIS; CARDIAC GRAFT REJECTION; CHICKENPOX; CHILD SAFETY; CHRONIC GRAFT VERSUS HOST DISEASE; CHURG STRAUSS SYNDROME; CLEFT LIP FACE PALATE; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CORPUS CALLOSUM AGENESIS; COUGHING; CROHN DISEASE; CRYPTOCOCCOSIS; CUTANEOUS VASCULITIDES; CYTOMEGALOVIRUS INFECTION; DEFECATION URGENCY; DERMATITIS; DERMATOLOGY; DERMATOMYOSITIS; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG HYDROLYSIS; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DRY EYE; DUODENITIS; DYSPEPSIA; DYSPNEA; DYSURIA; EAR MALFORMATION; ENCEPHALITIS; ENDOCARDITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; EPIDIDYMITIS; EPIGLOTTIS CANCER; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; ERYTHROCYTE APLASIA; ESCHERICHIA COLI INFECTION; ESOPHAGITIS; FACE DYSMORPHIA; FATIGUE; FETUS HYDROPS; FETUS MALFORMATION; FETUS RESORPTION; FINGER MALFORMATION; FURUNCULOSIS; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; GROUP B STREPTOCOCCAL INFECTION; HAND DISEASE; HEALTH CARE COST; HEMATURIA; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPOCOMPLEMENTEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFLAMMATION; INTESTINE INFECTION; INTESTINE VILLUS ATROPHY; ISCHEMIC COLITIS; KAPOSI SARCOMA; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; LEGIONNAIRE DISEASE; LEPROSY; LEUKOPENIA; LICHEN PLANUS; LIVER GRAFT REJECTION; LIVER TOXICITY; LUNG FIBROSIS; LUPUS ERYTHEMATOSUS; LYMPHOCYTE; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE DRUG DOSE; MICROSPORIDIOSIS; MICROTIA; MONOTHERAPY; MORPHEA; MOUTH ULCER; MUCORMYCOSIS; MYALGIA; MYASTHENIA GRAVIS; MYCOBACTERIOSIS; NAIL HYPOPLASIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; ONYCHOLYSIS; OPPORTUNISTIC INFECTION; OPTIMAL DRUG DOSE; PEMPHIGOID; PEMPHIGUS FOLIACEUS; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMOCYSTOSIS; PNEUMONIA; POMPHOLYX; PREGNANCY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PUVA; PYODERMA GANGRENOSUM; PYURIA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REMISSION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RETINITIS; REVIEW; SARCOIDOSIS; SCALP TUMOR; SCAR; SCLERODERMA; SEPTIC SHOCK; SEPTICEMIA; SIDE EFFECT; SKIN BLOOD VESSEL DISORDER; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; TERATOGENICITY; THORAX PAIN; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; TREMOR; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URTICARIA; VASCULITIS; VIRUS INFECTION; VOMITING; WEBER CHRISTIAN PANNICULITIS; WEGENER GRANULOMATOSIS; WERNICKE KORSAKOFF SYNDROME;

DERMATOLOGY; EDUCATION, MEDICAL, CONTINUING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; SKIN DISEASES;

EID: 58149334873     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.08.049     Document Type: Review

References (172)

1. Alsberg C.L., and Black O.F. Contribution to the study of maize deterioration; biochemical and toxicological investigations of Penicillium puberulum and Penicillium stoloniferum. Bull Burl Anim Ind US Dept Agr 270 (1913) 1-47
2. Florey H.W., Gilliver K., Jennings M.A., and Sanders A.C. Mycophenolic acid-an antibiotic from Penicillium brevicompactum. Lancet 1 (1946) 46-49
3. Cline J.C., Nelson J.D., Gerzon K., Williams R.H., and Delong D.C. In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds. Appl Microbiol 18 (1969) 14-20
4. Mitsui A., and Suzuki S. Immunosuppressive effect of mycophenolic acid. J Antibiot (Tokyo) 22 (1969) 358-363
5. Marinari R., Fleischmajer R., Schragger A.H., and Rosenthal A.L. Mycophenolic acid in the treatment of psoriasis: long-term administration. Arch Dermatol 113 (1977) 930-932
6. Jones E.L., Epinette W.W., Hackney V.C., Menedez L., and Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65 (1975) 537-542
7. Mydlarski P.R. Mycophenolate mofetil: a dermatologic perspective. Skin Therapy Lett 10 (2005) 1-6
8. Lee W.A., Gu L., Miksztal A.R., Chu N., Leung K., and Nelson P.H. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 7 (1990) 161-166
9. PDR Electronic Library. Mycophenolate mofetil (CellCept) product information [CD-ROM] (1995), Roche Laboratories, Nutley, NJ
10. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
11. Srinivas T.R., Herwig-Ulf M.K., and Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant 5 (2005) 207-217
12. Allison A.C., and Eugui E.M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10 1 Pt 2 (1996) 77-84
13. Allison A.C., and Eugui E.M. Immunosuppressive and other effects of MPA and an esther prodrug, mycophenolate mofetil. Immunol Rev 136 (1993) 5-28
14. Patel A.P., Swerlick R.A., and McCall C.O. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol 5 (2006) 390-391
15. Haufs M.G., Beissert S., Grabbe S., Schutte B., and Luger T.A. Psoriasis vulgaris treated successfully with mycophenolate mofetil. Br J Dermatol 138 (1998) 179-181
16. Geilen C.C., Arnold M., and Orfanos C.E. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 144 (2001) 583-586
17. Davidson S.C., Morris-Jones R., Powles A.V., and Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 143 (2000) 405-407
18. Pedraz J., Dauden E., Delgado-Jimenez Y., Garcia-Rio I., and Garcia-Diez A. Sequential study on the treatment of moderate-to-severe chronic plaque psoriasis with mycophenolate mofetil and cyclosporin. J Eur Acad Dermatol Venereol 20 (2006) 702-706
19. Zhou Y., Rosenthal D., Dutz F., and Ho V. Mycophenolate mofetil (CellCept) for psoriasis: a two-center prospective open-label clinical trial. J Cutan Med Surg 7 (2003) 193-197
20. Dauden E., Sanchez-Peinado C., Ruiz-Genao D., Garcia-F-Villalta M., Onate M.J., and Garcia-Diez A. Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br J Dermatol 150 (2004) 132-135
21. Carlin C.S., Feldman S.R., Krueger J.G., Krueger G.G., and Menter A. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endoint in the assessment of psoriasis. J Am Acad Dermatol 50 (2004) 859-866
22. Grundmann-Kollmann M., Mooser G., Schrader P., Zollner T., Kaskel P., Ochsendorf F., et al. Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J Am Acad Dermatol 42 5 Pt 1 (2000) 835-837
23. Wohlrab J., Jahn K., Plaetzer M., Neubert R., and Marsch W.C. Topical application of mycophenolate mofetil in plaque-type psoriasis. Br J Dermatol 144 (2001) 1263-1264
24. Bickle K.M., Roark T.R., and Hsu S. Autoimmune bullous dermatoses: a review. Am Fam Physician 65 (2002) 1861-1870
25. Grundmann-Kollmann M., Korting H.C., Behrens S., Kaskel P., Leiter U., Krahn G., et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 40 (1999) 957-960
26. Kirtschig G., and Nonhlanhla P.K. Management of bullous pemphigoid: recommendations for immunomodulatory treatments. Am J Clin Dermatol 5 (2004) 319-326
27. Esmaili N., Chams-Davatchi C., Valikhani M., Farshidfar F., Parvaneh N., and Tamizifar B. Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent. Eur J Dermatol 18 (2008) 159-164
28. Bohm M., Beissert S., Schwarz T., Metze D., and Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 349 (1997) 541
29. Nousari H.C., Sragovich A., Kimyai-Asadi A., and Orlinsky D. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 40 (1999) 265-268
30. Grundmann-Kollmann M., Kaskel P., Leiter U., Krahn G., Behrens S., Peter R.U., et al. Treatment of pemphigus vulgaris and bullouos pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 135 (1999) 724-725
31. Megahed M., Schmiedeberg S., Becker J., and Ruzicka T. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 45 (2001) 256-259
32. Powell A.M., Albert S., Al Fares S., Harman K.E., Setterfield J., Bhogal B., et al. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 149 (2003) 138-145
33. Sarma N., and Ghosh S. Mycophenolate mofetil as adjuvant in pemphigus vulgaris. Indian J Dermatol Venereol Leprol 73 (2007) 348-350
34. Beissert S., Werfel T., Frieling U., Böhm M., Sticherling M., Stadler R., et al. A comparison of oral methylprednisone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 142 (2006) 1447-1454
35. Beissert S., Werfel T., Frieling U., Böhm M., Sticherling M., Stadler R., et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol 143 (2007) 1536-1542
36. Tran M.M., Anhalt G.J., Barrett T., and Cohen B.A. Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent. J Am Acad Dermatol 47 (2002) 919-925
37. Kawashita M.Y., Tsai K., Aoki V., Santi C.G., Maruta C.W., and Rivitti E. Mycophenolate mofetil as an adjuvant therapy for classic and endemic pemphigus foliaceus. J Dermatol 32 (2005) 574-580
38. Benez A., and Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 144 (2001) 638-639
39. Grundmann-Kollmann M., Podda M., Ochsendorf F., Boehncke W.H., Kaufmann R., and Zollner T.M. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 137 (2001) 870-873
40. Neuber K., Schwartz I., Itschert G., and Dieck A.T. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 143 (2000) 385-391
41. Murray M.L., and Cohen J.B. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol 32 (2007) 23-27
42. Akhavan A., and Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 21 (2003) 225-240
43. Heller M., Shin H.T., Orlow S.J., and Schaffer J.V. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 157 (2007) 127-132
44. Satchell A.C., and Barnetson R. Staphylococcal septicaemia complicating treatment of atopic dermatitis with mycophenolate. Br J Dermatol 143 (2000) 202-203
45. Thomson M.A., Stewart D.G., and Lewis H.M. Chronic actinic dermatitis treated with mycophenolate mofetil. Br J Dermatol 152 (2005) 784-786
46. Nousari H.C., and Anhalt G.J. Mycophenolate in psoralen-UV-A desensitization therapy for chronic actinic dermatitis. Arch Dermatol 135 (1999) 1128-1129
47. Pickenacker A., Luger T.A., and Schwarz T. Dyshidrotic eczema treated with mycophenolate mofetil. Arch Dermatol 134 (1998) 378-379
48. Semhoun-Ducloux S., Ducloux D., and Miguet J.P. Mycophenolate mofetil-induced dyshidrotic eczema. Ann Intern Med 132 (2000) 417
49. Goyal S., and Nousari H.C. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45 (2001) 142-144
50. Schanz S., Ulmer A., Rassner G., and Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147 (2002) 174-178
51. Hanjani N.M., and Nousari C.H. Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement. Arch Dermatol 138 (2006) 1616-1618
52. Pisoni C.N., Obermoser G., Cuadrado M.J., Sanchez F.J., Karim Y., Sepp N.T., et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 23 (2005) 393-396
53. Pisoni C.N., Karim Y., and Cuadrado M.J. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14 Suppl 1 (2005) S9-11
54. Karim M.Y., Alba P., Cuadrado M.J., Abbs C., Cruz D.P.D., Khamashta M.A., et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41 (2002) 876-882
55. Mok C.C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 36 (2007) 329-337
56. Boehm I., and Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137 (2001) 235-236
57. Dooley M.A. Mycophenolate mofetil: what role in the treatment of lupus?. Lupus 15 (2006) 179-182
58. Albrecht J., Taylor L., Berlin J.A., Dulay S., Ang G., Fakharzadeh S., et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125 (2005) 889-894
59. Albrecht J., and Werth V.P. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 20 (2007) 93-101
60. Rowin J., Amato A.A., Deisher N., Curiso J., and Meriggioli M.N. Mycophenolate mofetil in dermatomyositis: is it safe?. Neurology 66 (2006) 1245-1247
61. Callen J.P., Edge J.C., Outland J.D., and Dempsey J.R. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol 142 (2006) 65-69
62. Majithia V., and Harisdangkul V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford) 44 (2005) 386-389
63. Tausche A.K., and Meurer M. Mycophenolate mofetil for dermatomyositis. Dermatology 202 (2001) 341-343
64. Gelber A.C., Nousari H.C., and Wigley F.M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 27 (2000) 1542-1545
65. Carroll C.L., Lang W., Snively B., Feldman S.R., Callen J., and Jorizzo J.L. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 158 (2008) 345-350
66. Gaines E., and Werth V.P. Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 300 (2008) 3-9
67. Russell J.P., and Gibson L.E. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol 45 (2006) 3-13
68. Le Hello C., Bonte I., Mora J., Verneuil L., and Guillevin L. Pyoderma gangrenosum associated with Wegner's granulomatosis: partial response to mycophenolate mofetil. Rheumatology 41 (2002) 236-237
69. Assaf C., Mewis G., Orfanos C.E., and Geilen C.C. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 150 (2004) 598
70. Thorne J.E., Hernandez M.I., Rencic A., and Nousari C.H. Severe scleritis and urticarial lesions. Am J Ophthalmol 134 (2002) 932-934
71. Worm M., and Kolde S.G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 143 (2000) 1324
72. Langford C.A., Talar-Williams C., and Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegner's granulomatosis. Arthritis Rheum 51 (2004) 278-283
73. Taverna J.A., Radfar A., Pentland A., Poggioli G., and Demierre M.F. Case reports: nodular vasculitis responsive to mycophenolate mofetil. J Drugs Dermatol 5 (2006) 992-993
74. Koukoulaki M., and Jayne D.R.W. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clinical Practice 102 (2006) 100-107
75. Adler Y.D., Mansmann U., and Zouboulis C.C. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Dermatology 203 (2001) 322-324
76. Plastira S.C., Vlachoyiannopoulos P.G., and Tzelepis G.E. Mycophenolate mofetil for interstitial lung disease in scleroderma. Rheumatology 45 (2006) 1572
77. Liossis S.N., Bounas A., and Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 45 (2006) 1005-1008
78. Swigris J.J., Olson A.L., Fischer A., Lynch D.A., Cosgrove G.P., Frankel S.K., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130 (2006) 30-36
79. Gerbino A.J., Goss C.H., and Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133 (2008) 455-460
80. Zamora A.C., Wolters P.J., Collard H.R., Connolly M.K., Elicker B.M., Webb W.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102 (2008) 150-155
81. Nihtyanova S.I., Brough G.M., Black C.M., and Denton C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology (Oxford) 46 (2007) 442-445
82. Stratton R.J., Wilson H., and Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40 (2001) 1192
83. Clements P.J., Lachenbruch P.A., Ng S.C., Simmons M., Sterz M., and Furst D.E. Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33 (1990) 1256-1263
84. Rose R.F., and Goodfield M.J.D. Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea. Clin Exp Dermatol 30 (2005) 226-228
85. Baudard M., Vincent A., Moreau P., Kergueris M.F., Harousseau J.L., and Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 30 (2002) 287-295
86. Takami A., Mochizuki K., Okumura H., Ito S., Suga Y., Yamazaki H., et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 83 (2006) 80-85
87. Hambach L., Stadler M., Dammann E., Ganser A., and Hertenstein B. Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogenic stem cell transplantation. Bone Marrow Transplant 29 (2002) 903-906
88. Busca A., Locatelli F., Marmont F., Audisio E., and Falda M. Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haematologica 88 (2003) 837-839
89. Baron F., Sandmaier B.M., Storer B.E., Maris M.B., Langston A.A., Lange T., et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 13 (2007) 1041-1048
90. Nash R.A., Johnston L., Parker P., McCune J.S., Storer B., Slattery J.T., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogenic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11 (2005) 495-505
91. Voglesang G.B., and Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 27 (2001) 1255-1262
92. Dorak C.C., Callard E., and Agarwal R. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogenic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplant 38 (2006) 253-254
93. Mori M., Muroi K., Matsuyama T., Oka S., Ono Y., Yamamoto C., et al. Benefits of mycophenolate mofetil for refractory graft-versus-host disease. Rinsho Ketsueki 48 (2007) 624-631
94. van Hest R.M., Doorduijn J.K., de Winter B.C., Cornelissen J.J., Vulto A.G., Oellerich M., et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 29 (2007) 385-390
95. Nousari H.C., Goyal S., and Anhalt G.J. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch Dermatol 135 (1999) 1420-1421
96. Frieling U., Bonsmann G., Schwarz T., Luger T.A., and Beissert S. Treatment of severe lichen planus with mycophenolate mofetil. J Am Acad Dermatol 49 (2003) 1063-1066
97. Tursen U., Api H., Kaya T., and Ikizoglu G. Treatment of lichen planopilaris with mycophenolate mofetil. Dermatol Online J 10 (2004) 24
98. Dalmau J., Puig L., Roé E., Peramiquel L., Campos M., and Alomar A. Successful treatment of oral erosive lichen planus with mycophenolate mofetil. J Eur Acad Dermatol Venereol 21 (2007) 259-260
99. Kouba D.J., Mimouni D., Rencic A., and Nousari H.C. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol 148 (2003) 147-148
100. Kilmartin D.J., Forrester J.V., and Dick A.D. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 352 (1998) 35-36
101. Chaussenot A., Bourg V., Chanalet S., Fornari J.M., and Lebrun C. Neurosarcoidosis treated with mycophenolate mofetil: two cases [in French]. Rev Neurol (Paris) 163 (2007) 471-475
102. Moudgil A., Przygodzki R.M., and Kher K.K. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol 21 (2006) 281-285
103. Davis M.D.P., Rogers R.S., and Pittelkow M.R. Recurrent erythema multiforme/Stevens-Johnson syndrome: response to mycophenolate mofetil. Arch Dermatol 138 (2002) 1547-1550
104. Boyd A.S. Use of mycophenolate mofetil in erythema nodosum. J Am Acad Dermatol 47 (2002) 968-969
105. Miehsler W., Reinisch W., Moser G., Gangl A., and Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?. Am J Gastroenterol 96 (2001) 782-787
106. Ford A.C., Towler R.J., Moayyedi P., Chalmers D.M., and Axon A.T.R. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 17 (2003) 1365-1369
107. Hohenleutner U., Mohr V.D., Michel S., and Landthaler M. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum. Lancet 350 (1997) 1748
108. Lee M.R., and Cooper A.J. Mycophenolate mofetil in pyoderma gangrenosum. J Dermatolog Treat 15 (2004) 303-307
109. Nousari H., and Petri D. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 134 (1998) 1509-1511
110. Daniels N.H., and Callen J.P. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 140 (2004) 1427-1429
111. Burdick A.E., and Ramirez C.C. The role of mycophenolate mofetil in the treatment of leprosy reactions. Int J Lepr Other Mycobact Dis 73 (2005) 127-128
112. Assman T., and Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol 20 (2002) 505-514
113. Kitchin J.E., Pomeranz M.K., Pak G., Washenik K., and Shupack J.L. Rediscovering mycophenolic acid: a review of its mechanism, side-effects, and potential uses. J Am Acad Dermatol 20 (2002) 505-514
114. Ducloux D., Ottignon Y., Semhoun-Ducloux S., Labbe S., and Saint-Hillier Y. Mycophenolate mofetil-induced villous atrophy. Transplantation 66 (1998) 1115-1116
115. Garrigue V., Canet S., Dereure O., Panabieres O., and Augias D. Oral ulcerations in renal transplant recipient: a mycophenolate mofetil-induced complication?. Transplantation 72 (2001) 968-969
116. Apostolou T., and Tsagalis G. Mycophenolate mofetil and oral ulcerations. Transplantation 77 (2003) 1911-1912
117. Hebert M.F., Ascher N.L., Lake J.R., Emond J., and Nilolai B. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 67 (1999) 707-712
118. Kim H.C., and Park S.B. Mycophenolate mofetil-induced ischemic colitis. Transplantation Proc 32 (2000) 1896-1897
119. Szyper-Kravitz M., Sheinberg P., Sidi Y., Schiffenbauer Y., and Trubniykov E. Hypersensitivity to mycophenolate mofetil in systemic lupus erythematosus: diagnostic measures and successful desensitization. Int Arch Allergy Immunol 138 (2005) 334-336
120. Rault R. Mycophenolate-associated onycholysis. Ann Intern Med 133 (2000) 921-922
121. Hantash B., and Fiorentino D. Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil. Arch Dermatol 142 (2006) 109-110
122. Chueh S.C., Huang C.Y., and Lai M.K. Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients. Transplant Proc 32 (2000) 1901-1902
123. Arbeiter K., Greenbaum L., Balzar E., Muller T., and Hofmeister F. Reproducible erythroid aplasia caused by mycophenolate mofetil. Pediatr Nephrol 14 (2000) 195-197
124. Gross D.C., Sasaki T.M., Buick M.K., and Light J.A. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation 64 (1997) 1607-1609
125. Shrestha N.K., Mossad S.B., and Braun W. Pneumonitis associated with the use of mycophenolate mofetil. Transplantation 75 (2003) 1762
126. Piccoli G.B., Rossetti M., Guarena C., Consiglio V., and Mezza E. Myalgia: an uncommon or underestimated side effect of mycophenolate mofetil after transplantation?. Nephrol Dial Transplant 19 (2004) 1940-1942
127. Powell A.M., Albert S., Fares S.A., Harman K.E., and Setterfield J. An evaluation of the usefulness of mycophenolate mofetil in pemphigus. Br J Dermatol 149 (2003) 138-145
128. Maes B., Oellerich M., Ceuppens J.L., Armstrong V.W., and Evenepoel P. A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. Nephrol Dial Transplant 17 (2002) 923-926
129. Frieling U., and Luger T.A. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clin Exp Dermatol 27 (2002) 562-570
130. Sarmiento J.M., Dockrell D.H., Schwab T.R., Munn S.R., and Paya C.V. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 14 (2000) 136-138
131. Birgerson LE. Change in CellCept label for pregnancy outcomes-dear healthcare professional letter. Nutley, NJ: Roche Pharmaceuticals. Available at: http://www.rocheusa.com/products/cellcept. Accessed June 6, 2008.
132. Rothwell W.S., Gloor J.M., Morgenstern B.Z., and Milliner D.S. Disseminated varicella infection in pediatric transplant recipients treated with mycophenolate mofetil. Transplantation 68 (1999) 158-161
133. Arash A., and Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 21 (2003) 225-240
134. Birgerson LE. Change in CellCept label for progressive multifocal leukoencephalopathy-dear healthcare professional letter. Nutley, NJ: Roche Pharmaceuticals. Available at: http://www.rocheusa.com/products/cellcept. Accessed June 6, 2008.
135. Neyts J., Andrei G., and DeClerq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 42 (1998) 216-222
136. O'Neill J.O., Edwards L.B., and Taylor D.O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the international society for heart and lung transplantation. J Heart Lung Transplant 25 (2006) 1186-1191
137. Lynch W.S., and Roenigk H.H. Mycophenolic acid for psoriasis. Arch Dermatol 113 (1977) 1203-1208
138. Vernino S., Salomao D.R., Habermann T.M., and O'Neill B.P. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology 65 (2005) 639-641
139. Finelli P.F., Naik K., DiGiuseppe J.A., and Prasad A. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus 15 (2006) 886-888
140. Waldman M.A., and Callen J.P. Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate. J Am Acad Dermatol 51 2 Suppl 1 (2004) S124-S130
141. Avalos-Peralta P., Herrera A., Rios-Martin J.J., Perez-Bernal A.M., and Moreno-Ramirez D. Localized Kaposi's sarcoma in a patient with pemphigus vulgaris. J Eur Acad Dermatol Venereol 20 (2006) 79-83
142. Kuypers D.R., Verleden G., Naesens M., and Vanrenterghem Y. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate glucuronosyltransferase. Clin Pharmacol Ther 78 (2005) 81-88
143. Husain S., and Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis 35 (2002) 53-61
144. Cattaneo D., Perico N., Gaspari F., Gotti E., and Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62 (2002) 1060-1067
145. Cattaneo D., Merlini S., Zenoni S., Baldelli S., and Gotti E. Influence of co-medication with sirolimus or cyclosproine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 5 (2005) 2937-2944
146. Pieper A.K., Buhle F., Bauer S., Mai I., and Budde K. The effect of sevelamer on the pharmacokinetics of cyclosporine A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant 19 (2004) 2630-2633
147. Morii M., Ueno K., Ogawa A., Kato R., and Yoshimura H. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 68 (2000) 613-616
148. Kato R., Ooi K., Ikura-Mori M., Tsuchishita Y., and Hashimoto H. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol 42 (2002) 1275-1280
149. Gelone D.K., Park J.M., and Lake K.D. Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. Pharmacotherapy 27 (2007) 1272-1278
150. Sankatsing S.U., Hoggard P.G., Huitema A.D., Sparidans R.W., and Kewn S. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet 43 (2004) 823-832
151. Royer B., Zanetta G., Berard M., Davani S., and Tanter Y. A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil. Clin Transplant 17 (2003) 158-161
152. Filler G., Hansen M., LeBlanc C., Lepage N., Franke D., Mai I., et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 19 (2004) 962-965
153. Wolverton S.E. Comprehensive dermatologic drug therapy (2001), WB Saunders, Philadelphia pp. 193-5
154. Tendron A., Gouyon J.B., and Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 17 (2002) 121-130
155. Sifontis N.M., Coscia L.A., Constantinescu S., Lavelanet A.F., Moritz M.J., and Armenti V.T. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 82 (2006) 1698-1702
156. Le Ray C., Coulomb A., Elefant E., Frydman R., and Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103 5 Pt 2 (2004) 1091-1094
157. Tjeertes I.F., Bastiaans D.E., van Ganzewinkel C.J., and Zegers S.H. Neonatal anemia and hydrops fetalis after maternal mycophenolate mofetil use. J Perinatol 27 (2007) 62-64
158. Armenti V.T., Radomski J.S., Moritz M.J., Gaughan W.J., Gulati R., McGrory C.H., et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl (2005) 69-83
159. Ettenger R., and Sarwal M.M. Mycophenolate mofetil in pediatric renal transplantation. Transplantation 80 Suppl 2 (2005) S201-S210
160. Alkali A.S., Bharati A., Yesudian P.D., Parslew R.A.G., and Field A. Oral 10, childhood mucous membrane pemphigoid: successful control with mycophenolate mofetil monotherapy. Br J Dermatol 156 (2007) 1406
161. Konstanze J., Fischer A., Neubert R.H.H., and Wohlrab J. Investigation of the penetration behaviour of mycophenolate mofetil from a semisolid formulation into human skin ex-vivo. J Pharm Pharmacol 53 (2001) 1581-1587
162. Johnston A., He X., and Holt D.W. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 82 (2006) 1413-1418
163. Budde K., Tedescop-Silva H., Pestana J.M., Glander P., Neumayer H.H., Felipe C.R., et al. Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: implications for therapeutic drug monitoring. Ther Drug Monit 29 (2007) 381-384
164. Masri M.A., Rizk S., Attia M.L., Barbouch H., and Rost M. Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. Transplant Proc 39 (2007) 1233-1236
165. Calvo N., Sanchez-Fructuoso A.I., Conesa J., Moreno A., and Barrientos A. Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium. Transplant Proc 38 (2006) 2396-2397
166. Videla C., and Godoy C. Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillence and outcome. Transplant Proc 39 (2007) 602-605
167. Koehl G.E., Wagner F., Stoeltzing O., Lang S.A., Steinbauer M., Schlitt H.J., et al. Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation 83 (2007) 607-614
168. Vedgso G., Sebestyen A., Paku S., Bama G., Hajdu M., Toth M., et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 31 (2007) 1003-1008
169. Gibson W.T., and Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 1110 (2007) 209-221
170. Herrera J., Ferrebuz A., MacGregor E.G., and Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17 12 Suppl 3 (2006) S218-S225
171. van Leuven S.I., Kastelein J.J., Allison A.C., Hayden M.R., and Stroes E.S. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles?. Cardiovasc Res 69 (2006) 341-347
172. Roos N., Poulalhon N., Farge D., Madelaine I., Mauviel A., and Verrecchia F. In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 321 (2007) 583-589